Ann: ResApp to Present at TechKnow Invest Roadshow Webinar, page-26

Mate, it's normal for a company in pre-revenue, or even in their first few years of revenue, not to provide revenue forecasts.

Based on your previous posts I would have thought you have been around long enough to know and understand this?

Regarding our revenue model however, I wonder if our insistance on a "per test" fee is a bit off-putting, especially to hospitals, perhaps not so much Telehealth platforms?

At the moment I think the company is only considering a licence fee for aid agencies active in the developing world, but I'd like to see us offer a yearly licence fee to hospitals, where it might not be as easy to pass on the per test fee to the patient?

I am somewhat surprised we haven't gone down this road with the hospitals in Australia where we already have developed relationships over many years and in-bedded champions such as at the Joondalup Health Campus, Perth Children's Hospital, Princess Margaret Hospital (PMH) in Perth, Wesley Hospital in Brisbane. These are the hospitals where we have conducted our Paediatric and Adult clinical trials.

This would have the additional positive effect of "smoothing" revenue in good and bad times.

There are thousands and thousands of hospitals to target in the countries where we have regulatory approvals. For example, there are 1,600 NHS hospitals in the UK alone, another +2,000 in Germany etc etc.